Treprostinil SR is under clinical development by Camurus and currently in Phase II for Raynauds Disease. According to GlobalData, Phase II drugs for Raynauds Disease have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Treprostinil SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Treprostinil SR overview
Treprostinil (CAM-2043) is under development for the treatment of pulmonary arterial hypertension and Raynaud’s disease secondary to systemic sclerosis. It is a sustained release injectable formulation and administered subcutaneously. It acts by targeting prostacyclin receptor. The drug candidate is a once-weekly liquid crystal gel formulation developed based on FluidCrystal injectable depot technology.
Camurus overview
Camurus, a subsidiary of Sandberg Development AB, is a pharmaceutical company. It carries out development and commercialization of treatments for the patients suffering from chronic diseases. The company’s major products include CAM2038 to treat chronic pain; CAM2029 to treat acromegaly, GEP-NET and PLD; CAM4072 to treat genetic obesity disorders; CAM2032 to treat Prostate cancer; CAM2043 to treat pulmonary arterial hypertension and raynaud’s phenomenon; CAM4071 to treat endocrine disorders; buvidal drug candidates. It sells drugs under the brand name of Episil, FluidCrystal. The company has developmental and commercial collaborations with biotechnology and pharmaceutical companies for product development. Camurus is headquartered in Lund, Sweden.
For a complete picture of Treprostinil SR’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#Treprostinil #Camurus #Raynauds #Disease #Likelihood #Approval
